HONG KONG and BEIJING – Hong Kong-listed China Grand Pharmaceutical and Healthcare Holdings Ltd. and Niel, Belgium-based mRNA vaccine specialist Etherna Immunotherapies NV are setting up a joint venture to develop, produce and commercialize mRNA prophylactic and therapeutic vaccines.
An international study led by Nanyang Technological University in Singapore has designed and synthesized broad-spectrum antimicrobial polymers (AMPs) and demonstrated the safety and efficacy of two such agents against multidrug-resistant (MDR) bacteria in mouse models of sepsis.
Researchers at the University of California at San Francisco have developed a method to diagnose any known pathogen from any body fluid within a day – or, depending on the sequencing method, within a few hours. For an unknown pathogen, the method spits out its nearest known relative.
Assembly Biosciences Inc., a company testing the limits of sustained virologic response in people with chronic hepatitis B virus infection after they discontinue treatment, said nearly all participants in an ongoing phase II study returned to having detectable viral loads after going off a regimen featuring the company's core inhibitor, vebicorvir.
It didn’t take long for a U.S. district judge to grant Gilead Sciences Inc.’s request for a temporary restraining order to stop two interconnected health care networks in Florida from defrauding the company’s Advancing Access Medication Assistance Program that provides free HIV pre-exposure prophylaxis drugs to eligible, uninsured people.
A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain.
DUBLIN – Kiadis Pharma BV has parlayed its €31.9 million (US$37.2 million) stock-based acquisition of Cytosen Therapeutics Inc. last year, which involved an initial outlay of just €14.5 million worth of shares, into a €308 million payday with Sanofi SA.
In Regeneron Pharmaceuticals Inc.’s Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), the FDA has approved its first ever treatment for the Ebola virus in pediatric and adult patients.
Monday, Oct. 5, was probably the first day of 2020 that SARS-CoV-2 had serious competition for science media attention – by another virus. The Nobel Assembly awarded the 2020 Nobel Prize for Physiology or Medicine to Harvey Alter, Michael Houghton and Charles Rice “for the discovery of hepatitis C virus.”
RSS
